AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares traded -1.41% lower at $0.70 on Wall Street last session.
In accordance with the data, 2 analysts cover AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX). The consensus rating among analysts is ‘Overweight’. ACRX stock price is now -60.94% away from the 50-day moving average and -80.02% away from the 200-day moving average. The market capitalization of the company currently stands at $5.10M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 1 analysts and a buy by 1.
On November 11, 2019, Credit Suisse Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock reducing its target price from $7 to quote $2, while the Credit Suisse previously rated the stock as ‘Outperform’ on August 05, 2019.
In other news, Angotti Vincent J., Chief Executive Officer bought 46,400 shares of the company’s stock on Jun 07. The stock was bought for $10,333 at an average price of $0.22. Upon completion of the transaction, the Chief Executive Officer now directly owns 1,016,919 shares in the company, valued at $0.71 million. Insiders disposed of 9,725 shares of company stock worth roughly $6807.5 over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACRX stock. A new stake in AcelRx Pharmaceuticals Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $257,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $44,000 in shares of ACRX during the first quarter. In the first quarter, CITIGROUP INC acquired a new stake in AcelRx Pharmaceuticals Inc. valued at approximately $3,000. In total, there are 49 active investors with 12.40% ownership of the company’s stock.
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) opened at $0.6881 on Thursday. During the past 12 months, AcelRx Pharmaceuticals Inc. has had a low of $0.61 and a high of $7.68. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 1.60, and a quick ratio of 1.50. The fifty day moving average price for ACRX is $1.7922 and a two-hundred day moving average price translates $3.4996 for the stock.
The latest earnings results from AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) was released for Sep, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.94, beating analysts’ expectations of -$1.2 by 0.26. This compares to -$1.41 EPS in the same period last year. The company reported revenue of $0.51 million for the quarter, compared to $1.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -72.77 percent. For the current quarter, analysts expect ACRX to generate $4.5M in revenue.
AcelRx Pharmaceuticals Inc.(ACRX) Company Profile
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
